Cite
Goud R, Lufkin B, Duffy J, et al. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries. JAMA Intern Med. 2021;181(12):1623-1630doi: 10.1001/jamainternmed.2021.6227.
Goud, R., Lufkin, B., Duffy, J., Whitaker, B., Wong, H. L., Liao, J., Lo, A. C., Parulekar, S., Agger, P., Anderson, S. A., Wernecke, M., MaCurdy, T. E., Weintraub, E., Kelman, J. A., & Forshee, R. A. (2021). Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries. JAMA internal medicine, 181(12), 1623-1630. https://doi.org/10.1001/jamainternmed.2021.6227
Goud, Ravi, et al. "Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries." JAMA internal medicine vol. 181,12 (2021): 1623-1630. doi: https://doi.org/10.1001/jamainternmed.2021.6227
Goud R, Lufkin B, Duffy J, Whitaker B, Wong HL, Liao J, Lo AC, Parulekar S, Agger P, Anderson SA, Wernecke M, MaCurdy TE, Weintraub E, Kelman JA, Forshee RA. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries. JAMA Intern Med. 2021 Dec 01;181(12):1623-1630. doi: 10.1001/jamainternmed.2021.6227. PMID: 34724025; PMCID: PMC8561433.
Copy
Download .nbib